Back
[Diagnostics and treatment of acromegaly : Necessity for targeted monitoring of comorbidities].
Journal article

[Diagnostics and treatment of acromegaly : Necessity for targeted monitoring of comorbidities].

  • Petersenn S ENDOC Praxis für Endokrinologie, Andrologie und medikamentöse Tumortherapie, Erik-Blumenfeld-Platz 27A, 22587, Hamburg, Deutschland. stephan.petersenn@endoc-med.de.
  • Christ-Crain M Endokrinologie, Diabetologie & Metabolismus, Universitätsspital Basel, Basel, Schweiz.
  • Droste M Endokrinologie, Diabetologie, Hormonanalytik, Medicover MVZ, Oldenburg, Deutschland.
  • Finke R Innere Medizin, Endokrinologie/Diabetologie & Allgemeinmedizin, Praxisgemeinschaft an der Kaisereiche, Berlin, Deutschland.
  • Flitsch J Klinik und Poliklinik für Neurochirurgie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
  • Kreitschmann-Andermahr I Neurochirurgische Klinik, Universitätsklinikum Essen, Universität Duisburg-Essen, Essen, Deutschland.
  • Luger A Klinische Abteilung für Endokrinologie & Stoffwechsel, Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Wien, Österreich.
  • Schopohl J Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, München, Deutschland.
  • Stalla G Innere Medizin, Endokrinologie und Klinische Chemie, Max-Planck-Institut für Psychiatrie, München, Deutschland.
Show more…
  • 2017-10-14
Published in:
  • Der Internist. - 2017
Cardiovascular diseases
Endocrine system diseases
Insulin-like growth factor I
Pituitary adenoma
Sleep apnea syndromes
Acromegaly
Adenoma
Comorbidity
Diagnosis, Differential
Growth Hormone-Secreting Pituitary Adenoma
Humans
Insulin-Like Growth Factor I
Interdisciplinary Communication
Intersectoral Collaboration
Rare Diseases
English Acromegaly is a rare and severe condition, presenting with typical signs and symptoms. The diagnosis is often initially made years after the first manifestations of the disease. In more than 99% of patients the disease is caused by a benign pituitary tumor that secretes growth hormone (GH). The diagnosis is based on the presence of increased insulin-like growth factor 1 (IGF-1) levels and a lack of GH suppression in the oral glucose tolerance test. The standard imaging procedure for tumor detection is magnetic resonance imaging in the region of the sella turcica. Treatment includes surgical, drug and radiation therapy. Important factors are an intensive aftercare of the patient, controls for detection of tumor recurrence and pituitary insufficiency as well as assessment of various organ functions and risk constellations. Patient care should involve close cooperation between endocrinologists, neurosurgeons and general practitioners as well as other specialist disciplines.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/232516
Statistics
Document views: 14 File downloads: